



Clinical trial results:

Multicenter randomized, double-blind, placebo-controlled parallel clinical trial to assess efficacy and safety of Omalizumab (Xolair®) in a new indication: cholinergic urticaria.

Summary

EudraCT number	2013-002770-43
Trial protocol	ES
Global end of trial date	22 June 2017

Results information

Result version number	v1 (current)
This version publication date	04 November 2021
First version publication date	04 November 2021
Summary attachment (see zip file)	Final report summary (Resumen informe final CUN-OMAL-UCOL v1 de 02-05-2018.pdf)

Trial information

Trial identification

Sponsor protocol code	CUN-OMAL-UCOL
-----------------------	---------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Clínica Universidad de Navarra
Sponsor organisation address	Avda. Pío XII, 36, Pamplona, Spain, 31008
Public contact	UCEC, Clínica Universidad de Navarra, 34 948255 400, ucicec@unav.es
Scientific contact	UCEC, Clínica Universidad de Navarra, 34 948255 400, ucicec@unav.es

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	18 April 2018
Is this the analysis of the primary completion data?	Yes
Primary completion date	22 June 2017
Global end of trial reached?	Yes
Global end of trial date	22 June 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Our primary endpoint will be the negativization of the exercise challenge test: We will perform the exercise challenge test following the European Guidelines

Protection of trial subjects:

NA

Background therapy:

No treatment available. Antihistamines that normally control the symptoms of other types of urticaria partially relieve symptoms in cholinergic urticaria

Evidence for comparator:

NA

Actual start date of recruitment	19 December 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 22
Worldwide total number of subjects	22
EEA total number of subjects	22

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	3
Adults (18-64 years)	19
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Recruitment took place over two years to reach 22 evaluable patients

Pre-assignment

Screening details:

Patients with a clinical diagnosis of cholinergic urticaria by history and a positive exercise challenge test were treated with double license dose of cetirizine (20 mg) for two weeks and the exercise challenge test was repeated. If the test was again positive, they were randomized to start the study.

Pre-assignment period milestones

Number of subjects started	22
Number of subjects completed	22

Period 1

Period 1 title	Treatment (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst

Arms

Are arms mutually exclusive?	Yes
Arm title	Arm A (treatment group)

Arm description:

This is a multicenter randomized, double-blind, placebo-controlled Parallel Clinical Trial clinical trial. If the test was positive, patients were randomized to placebo or active treatment for 12 weeks receiving a monthly dose during the blinded period. From week 16th, all patients received omalizumab and performed exercise challenge test in each visit. We followed up patients three months after the last dose performing an exercise challenge test.

Arm type	Experimental
Investigational medicinal product name	Omalizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

It is administered subcutaneously in the deltoid region of the arm. The dose is 300mg. It is administered as two subcutaneous injections of 150mg in 1ml each.

Arm title	Arm B (placebo group)
------------------	-----------------------

Arm description:

This is a multicenter randomized, double-blind, placebo-controlled Parallel Clinical Trial clinical trial. If the test was positive, patients were randomized to placebo or active treatment for 12 weeks receiving a monthly dose during the blinded period. From week 16th, all patients received omalizumab and performed exercise challenge test in each visit. We followed up patients three months after the last dose performing an exercise challenge test.

Arm type	Placebo
----------	---------

Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

2ml of Physiological Saline is administered as two injections of 1ml each, subcutaneosly in the deltoid region of the upper arm. The volume to be administered is the same as that of the active treatment.

Number of subjects in period 1	Arm A (treatment group)	Arm B (placebo group)
Started	13	9
Completed	13	9

Baseline characteristics

Reporting groups

Reporting group title	Treatment
-----------------------	-----------

Reporting group description: -

Reporting group values	Treatment	Total	
Number of subjects	22	22	
Age categorical			
Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	3	3	
Adults (18-64 years)	17	17	
From 65-84 years	2	2	
85 years and over	0	0	
Age continuous			
32.3 (13.8) for placebo and 35.4 (16.2) for treatment			
Units: years			
arithmetic mean	34.1		
standard deviation	± 15.00	-	
Gender categorical			
Units: Subjects			
Female	6	6	
Male	16	16	

End points

End points reporting groups

Reporting group title	Arm A (treatment group)
-----------------------	-------------------------

Reporting group description:

This is a multicenter randomized, double-blind, placebo-controlled Parallel Clinical Trial clinical trial. If the test was positive, patients were randomized to placebo or active treatment for 12 weeks receiving a monthly dose during the blinded period. From week 16th, all patients received omalizumab and performed exercise challenge test in each visit. We followed up patients three months after the last dose performing an exercise challenge test.

Reporting group title	Arm B (placebo group)
-----------------------	-----------------------

Reporting group description:

This is a multicenter randomized, double-blind, placebo-controlled Parallel Clinical Trial clinical trial. If the test was positive, patients were randomized to placebo or active treatment for 12 weeks receiving a monthly dose during the blinded period. From week 16th, all patients received omalizumab and performed exercise challenge test in each visit. We followed up patients three months after the last dose performing an exercise challenge test.

Primary: negativization of the exercise challenge test

End point title	negativization of the exercise challenge test
-----------------	---

End point description:

Our primary endpoint will be the negativization of the exercise challenge test: We will perform the exercise challenge test following the European Guidelines

End point type	Primary
----------------	---------

End point timeframe:

To better assess the safety of the medication in the indication under study, the blind clinical trial comprising 4 months will be followed by an open label period of 8 months in which all patients will receive the active drug (pharmacovigilance period)

End point values	Arm A (treatment group)	Arm B (placebo group)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	13	9		
Units: +/-	13	9		

Statistical analyses

Statistical analysis title	Comparasion of means
----------------------------	----------------------

Statistical analysis description:

Differences in the distribution of categorical variables were tested using the chi-square test or the Fisher's exact test. The correlation between negativization outcome and visit was quantified using the Spearman's rank correlation coefficient. Statistical significance was defined using a 2-sided α level of 0.05.

Comparison groups	Arm B (placebo group) v Arm A (treatment group)
-------------------	---

Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	
P-value	≤ 0.05 ^[1]
Method	Spearman's rank correlation coefficient

Notes:

[1] - We observed a significant correlation between negativization outcomes and visit (Spearman Rho: 0,65; $p=0,004$). We found an average negativization increase of 2.9 percentage points (IC 95%: 1,5; 4,2) per visit.

Adverse events

Adverse events information

Timeframe for reporting adverse events:

2 years

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	none
-----------------	------

Dictionary version	0
--------------------	---

Reporting groups

Reporting group title	All the patients
-----------------------	------------------

Reporting group description: -

Serious adverse events	All the patients		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 22 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	All the patients		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	13 / 22 (59.09%)		
General disorders and administration site conditions			
Headache			
subjects affected / exposed	2 / 22 (9.09%)		
occurrences (all)	2		
Pharyngitis			
subjects affected / exposed	2 / 22 (9.09%)		
occurrences (all)	2		
Metallic flavor			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences (all)	1		
Sciatica			

subjects affected / exposed	1 / 22 (4.55%)		
occurrences (all)	1		
Low back pain			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences (all)	1		
Restless legs syndrome			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences (all)	1		
Paraphimosis			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences (all)	1		
Phimosis surgery			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences (all)	1		
Cold with bronchial hyperreactivity			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences (all)	1		
Musculoskeletal and connective tissue disorders			
Ankle sprain			
subjects affected / exposed	1 / 22 (4.55%)		
occurrences (all)	1		
Metabolism and nutrition disorders			
Food poisoning	Additional description: Seafood		
subjects affected / exposed	1 / 22 (4.55%)		
occurrences (all)	1		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
05 February 2014	Adding new centers
07 August 2014	Adding new centers
26 January 2015	Adding new centers

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported